Gallstones and gallstone diseases, therefore, are a frequent and important clinical problem.
The book addresses the basic aspects of gallstone pathogenesis as well as the non-surgical and surgical treatment of gallstone diseases.
List of principal contributors. Preface. Section I: Epidemiology And Genetics. 1: Risk factors and natural history of gallstone disease; W Kratzer. 2: Low phospholipid-associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene; O Rosmorduc, R Poupon. 3: Cholesterol 7 alpha-hydroxylase (CYP7A1) gene mutation: another cause for gallstone formation?; CR Pullinger, C Eng, MJ Malloy, JP Kane. 4: Cystic fibrosis transmembrane conductance regulator gene mutations cause `black' pigment gallstone formation: new insights from mouse models and implications for therapeutic interventions in cystic fibrosis; AL Broderick, H Wittenburg, MA Lyons, KDR Setchell, AF Hofmann, MC Carey. 5: Molecular genetics of gallstone formation: human association studies and comparative genomics; F Lammert, HE Wasmuth, S Matern. Section II: Biliary Lipid Secretion. 6: Hepatocellular transport of cholesterol; M Fuchs. 7: Effect of an Abcc2 missense mutation on biliary lipid secretion and lithogenicity of bile; G Bouchard, MC Carey, B Paigen. 8: The role of ABCG5 and ABCG8 in biliary lipid secretion; E Vink, A Kosters, RJJM Frijters, AK Groen. 9: Biphasic response of hepatobiliary cholesterol metabolism to leptin at the onset of diet-induced obesity; S Roy, DE Cohen. 10: Epidemiology and molecular pathogenesis of primary hepatolithiasis; J Shoda, N Tanaka, T Osuga. 11: Bilirubin and cholesterol gallstone formation: phospholipase and &bgr;-glucuronidase as factors affecting cholesterol crystallization; S Tazuma, Y Sunami, K Nakai, T Nishioka, H Hyogo, K Kanno, Y Numata, A Yamaguchi, D Komichi, T Kobuke, M Nonaka, K Iwamoto, M Inoue, Y Nabeshima, M Ogi, T Ishitobi, T Ajima, K Chayama. Section III: Gallbladder Function And Lipid Absorption. 12: Gene polymorphisms and impaired gallbladder motility; DM Klass. 13: Molecular dynamics simulation of cholesterol nucleation in mixed micelles modelling human bile; SJ Marrink. 14: Pigment gallstones: an intestinal disease?; N Méndez-Sánchez, N Chavez-Tapia, K Sánchez, J Bordes, M Uribe. 15: Bile acid transporters and cholelithiasis; I Bergheim, S Harsch, O Mueller, S Schimmel, P Fritz, EF Stange. 16: Reconstitution of fat absorption by phosphatidylcholine-cholesterol vesicles during bile deficiency in rats; HJ Verkade, R Havinga, S Tazuma, H Elzinga, F Stellaard, F Kuipers, T Nishioka. Section IV: Non-Surgical Treatment Of Gallstone Disease. 17: Non-surgical treatment of gallbladder stones: still a role for ursodeoxycholic acid?; U Beuers. 18: Prevention of gallstone-related complications with ursodeoxycholic acid; GP van Berge-Henegouwen, NG Venneman, P Portincasa, KJ van Erpecum. 19: Fatty acid bile acid conjugates – novel agents for prevention and treatment of gallstones; FM Konikoff, A Frenkel, T Gilat. 20: Gallstone pancreatitis; KJ van Erpecum, NG Venneman, LP Van Minnen, GP van Berge Henegouwen. 21: Imaging of bile duct stones; M Sackmann, K-D Schmidt. 22: Endoscopic therapy of bile duct stones; H Schwacha. Section V: Surgical Treatment Of Gallstone Disease. 23: Surgical treatment of gallstone disease – always laparoscopic?; UT Hopt. 24: Complications of laparoscopic cholecystectomy; KP Thon. 25: Postcholecystectomy syndrome; D Jüngst, G Straub, G Sauter. 26: State of the art – gallstone research in the post-genomic era; MC Carey, RS Kwon, KJ Maurer, JG Fox. Colour figures. Index.
